Searchable abstracts of presentations at key conferences in endocrinology

ea0028p62 | Clinical practice/governance and case reports | SFEBES2012

Web-based 360-degree assessment survey to assess care and service improvement needs in an Endocrine unit

Gordon Nadia , Prague Julia , Aylwin Simon JB

Context: Better, reproducible and structured methods of assessing care provided to endocrine patients are needed. Similarly, access to regional units and referral pathways could be improved with nationally agreed standards for waiting times.Objective: To gain views on the current level of patient care and how services might be improved using a 360-degree assessment process.Method: Three web based surveys were created using SurveyMo...

ea0094p366 | Neuroendocrinology and Pituitary | SFEBES2023

MGMT and MSH2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: a single centre case series

Whitelaw Ben , Gilbert Jackie , Ling Chuah Ling , Crane James , Dimitriadis Georgios , Thomas Nick , Barazi Sinan , Maratos Eleni , Shapey Jonathan , Laniba Leah , Lazaro Nila , Gordon Nadia , Al-Salihi Omar , King Andrew , Al-Sarraj Safa , Reisz Zita , Bodi Istvan , Al Busaidi Ayisha , U-King-IM Jean-Marie , Aylwin Simon

Temozolomide has an established role as first line chemotherapy for aggressive pituitary adenoma and carcinoma. There are mixed reports whether the MGMT (methylguanine methyltransferase) and mismatch repair protein (MSH2/6) status of a tumour, assessed by immunohistochemistry (IHC) can predict response to temozolomide. This is the first series to assess combined MGMT and MSH2 status. We analysed a retrospective case series of patients treated with temozolomide at our tertiary ...